Deerfield Management MNKD Position
ExitedDeerfield Management exited their position in MannKind Corporation (MNKD) in Q4 2024, after holding the stock for 4 quarters.
The position was first reported in Q1 2024 and has been tracked across 4 quarterly 13F filings.
2 other tracked funds also hold MNKD.
There is an upcoming Phase 2 readout for Technosphere Insulin in 230 days (Nov 30, 2026), making the timing of Deerfield's position particularly relevant.
About MannKind Corporation
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect cells against inflammatory conditions. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.
Full company profile →Short Interest
7.5%
3.0 days to cover
Deerfield Management MNKD Position History
Frequently Asked Questions
Does Deerfield Management own MNKD?
No. Deerfield Management exited their position in MannKind Corporation (MNKD) in Q4 2024. They previously held the stock for 4 quarters.
How many hedge funds own MNKD?
2 specialist biotech hedge funds currently hold MNKD, including Avoro Capital Advisors, EcoR1 Capital. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Deerfield Management first buy MNKD?
Deerfield Management's position in MNKD was first reported in Q1 2024. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Deerfield Management's MNKD position increasing or decreasing?
Deerfield Management completely exited their MNKD position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
MNKDCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Deerfield ManagementPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →